Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1626 - 1650 of 2386 in total
BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).
Investigational
Investigational
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to...
Investigational
Matched Description: … investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
GC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov...
Experimental
Matched Description: … These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19. …
Matched Categories: … Experimental Unapproved Treatments for COVID-19
Isoquercitrin is under investigation in clinical trial NCT04622865 (Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19).
Investigational
Matched Description: … With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Experimental
Matched Iupac: … sodium 8-hydroxy-7-iodoquinoline-5-sulfonic acid hydrogen carbonate …
Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).
Investigational
Matched Description: … Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19
Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.
Investigational
Resolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).
Investigational
Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)).
Investigational
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
Investigational
Matched Description: … investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, …
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional …
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and...
Investigational
Matched Description: … Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
Investigational
Matched Iupac: … ),17',19'(24')-tetraene-13',13',15'-trione ... (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H-20'-oxa-13'lambda6 ... -thia-1',14'-diazaspiro[naphthalene-1,22'-tetracyclo[14.7.2.0^{3,6}.0^{19,24}]pentacosane]-8',16'(25' …
Teropavimab is under investigation in clinical trial NCT05729568 (A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection).
Investigational
Investigational
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational
CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
Investigational
Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Matched Description: … Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19
Investigational
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Investigational
Displaying drugs 1626 - 1650 of 2386 in total